osanetant
Small moleculeexperimental
Clinical trial activity
3 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Mar 30, 2022 (NCT05325775)
Timeline
2020s
- Jan 1, 2022
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Neurokinin 3 receptorANTAGONIST
TACR3 antagonist
Chemistry & pharmacology
Loading structure…
SMILES
CC(=O)N(C)C1(c2ccccc2)CCN(CCC[C@]2(c3ccc(Cl)c(Cl)c3)CCCN(C(=O)c3ccccc3)C2)CC1- Mol. weight
- 606.64 g/mol
- Lipinski Ro5
- 2 violation(s)
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL346178 ↗
Also known as
- osanetant
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05647447 | Early Phase 1 (Phase 1) | Jan 31, 2023 | University of Kansas |
| NCT05607342 | Early Phase 1 (Phase 1) | Nov 30, 2022 | University of Kansas |
| NCT05325775 | Phase 1/Phase 2 (Phase 2) | Mar 30, 2022 | Acer Therapeutics, Spaulding Clinical Research Inc. |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| University of Kansas | Academic/Hospital | 2 | 2 | 1 | 2022 |
| Acer Therapeutics | For profit | 1 | 1 | 1 | 2022 |
| Spaulding Clinical Research Inc. | For profit | 1 | 0 | 1 | 2022 |
3 organizations
Page 1 / 1